Subscribe

1933 Industries Inc. (TGIF.CN)

CAD0.01 +0.01 (+100.00%)
CA CNQ Healthcare Drug Manufacturers - Specialty & Generic
Address 1055 West Hastings Street V6E 2E9
Vancouver, BC, CA
CEO Brian Farrell
Website 1933industries.com
IPO 2009-02-09
ISIN CA65442F1053

Explore sections of this company profile

Also trades on Canadian Securities Exchange · TGIF.CN (CAD) Other OTC · TGIFF (USD)
Description

1933 Industries Inc. is a Vancouver, Canada-based cannabis company engaged in the cultivation and production of cannabis products throughout the United States and Canada. The firm develops, packages, and markets an extensive range of cannabidiol (CBD)-infused items, catering to both the medical and recreational cannabis sectors. Under its Canna Hemp and Canna Hemp X brands, these CBD offerings include tinctures, vape pens, cartridges, topical lotions, pain creams, gummies, and capsules. Beyond CBD, the company also supplies traditional cannabis flowers and concentrates. Consumers can acquire its CBD-infused products via retail dispensaries, other retail establishments, and its dedicated e-commerce platform. The company officially changed its name from Friday Night Inc. to 1933 Industries Inc. in September 2018.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CAD0.01 +0.01 (+100.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
89.2K
Beta
1.59
Float Shares
482.19M
Free Float %
92.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% -50.00% -50.00% -50.00% +0.00% -60.00% +0.00% -66.67% -94.74% -93.75% -99.69%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.01
Ratings Trend (MoM)
Rating 2025-05 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-7.85
Distress
Piotroski F-Score
6 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -9.8% Q2'26: -9.3% (vs Q2'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +83.3% ★ Q2'26: -12.5% (vs Q2'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +0.5% Q2'26: +4.9% (vs Q2'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +4.0% Q2'26: -8.2% (vs Q2'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +3.4% Q2'26: -12.0% (vs Q2'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +2.7% Q2'26: +6.2% (vs Q2'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    17.50× Q2'26: -11.78× (vs Q2'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.68) × ERP
WACC = 12% × Ke + 88% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.01
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Jul 2019
actual 		Jul 2020
actual 		Jul 2021
actual 		Jul 2022
actual 		Jul 2023
actual 		Jul 2024
actual 		Jul 2025
actual 		Jul 2026
1 Rev. Ana.
1 EPS Ana. 		Jul 2027
1 Rev. Ana.
1 EPS Ana. 		Jul 2028
1 Rev. Ana.
1 EPS Ana. 		Jul 2029
1 Rev. Ana.
1 EPS Ana.
Revenue
18.06M
est: 18.00M (+0.3%)
11.96M
est: 12.60M (-5.1%)
11.98M
est: 20.50M (-41.6%)
12.54M
est: 18.00M (-30.3%)
18.27M
est: 12.60M (+45.0%)
19.35M
est: 20.50M (-5.6%)
17.45M
est: 18.00M (-3.1%)
18.00M
18.00M – 18.00M
+0.0% YoY
18.00M
18.00M – 18.00M
+0.0% YoY
12.60M
12.60M – 12.60M
-30.0% YoY
20.50M
20.50M – 20.50M
+62.7% YoY
EBITDA
-16.21M
est: -6.12M (-164.7%)
-14.26M
est: -4.29M (-232.7%)
-2.71M
est: -6.97M (+61.2%)
-13.83M
est: -6.12M (-125.9%)
-10.03M
est: -4.29M (-134.0%)
313.7K
est: -6.97M (+104.5%)
1.01M
est: -6.12M (+116.4%)
-6.12M
-6.12M – -6.12M
+0.0% YoY
-6.12M
-6.12M – -6.12M
+0.0% YoY
-4.29M
-4.29M – -4.29M
+30.0% YoY
-6.97M
-6.97M – -6.97M
-62.7% YoY
EBIT
-16.86M
est: -7.20M (-134.0%)
-16.45M
est: -5.04M (-226.1%)
-3.70M
est: -8.21M (+54.9%)
-15.76M
est: -7.20M (-118.7%)
-11.72M
est: -5.04M (-132.5%)
-1.77M
est: -8.21M (+78.5%)
704.0K
est: -7.20M (+109.8%)
-7.20M
-7.20M – -7.20M
+0.0% YoY
-7.20M
-7.20M – -7.20M
+0.0% YoY
-5.04M
-5.04M – -5.04M
+30.0% YoY
-8.21M
-8.21M – -8.21M
-62.7% YoY
Net Income
-18.54M
est: -29.43M (+37.0%)
-20.02M
est: -29.43M (+32.0%)
-6.29M
est: -9.81M (+35.9%)
-18.07M
est: -29.43M (+38.6%)
-13.36M
est: -29.43M (+54.6%)
-1.14M
est: -9.81M (+88.4%)
-217.0K
est: -29.43M (+99.3%)
-29.43M
-29.43M – -29.43M
+0.0% YoY
-29.43M
-29.43M – -29.43M
+0.0% YoY
-29.43M
-29.43M – -29.43M
+0.0% YoY
-9.81M
-9.81M – -9.81M
+66.7% YoY
SGA
14.62M
est: 6.43M (+127.3%)
16.73M
est: 4.50M (+271.6%)
7.94M
est: 7.33M (+8.4%)
7.21M
est: 6.43M (+12.1%)
5.13M
est: 4.50M (+13.8%)
3.06M
est: 7.33M (-58.2%)
1.91M
est: 6.43M (-70.2%)
6.43M
6.43M – 6.43M
+0.0% YoY
6.43M
6.43M – 6.43M
+0.0% YoY
4.50M
4.50M – 4.50M
-30.0% YoY
7.33M
7.33M – 7.33M
+62.7% YoY
EPS
-0.07
est: -0.06 (-22.5%)
-0.07
est: -0.06 (-16.5%)
-0.02
est: -0.02 (+19.0%)
-0.04
est: -0.06 (+33.2%)
-0.03
est: -0.06 (+51.2%)
0.00
est: -0.02 (+88.0%)
0.00
est: -0.06 (+99.3%)
-0.06
-0.06 – -0.06
+0.0% YoY
-0.06
-0.06 – -0.06
+0.0% YoY
-0.06
-0.06 – -0.06
+0.0% YoY
-0.02
-0.02 – -0.02
+66.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-27 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-26 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-25 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-21 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-15 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-13 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-12 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-11 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-08 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-07 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-06 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-05-05 C+ 2/5 1/5 1/5 4/5 1/5 4/5 1/5
2026-05-04 C+ 2/5 1/5 1/5 4/5 1/5 4/5 1/5
2026-05-01 C+ 2/5 1/5 1/5 4/5 1/5 4/5 1/5
2026-04-30 C+ 2/5 1/5 1/5 4/5 1/5 4/5 1/5
2026-04-29 C+ 2/5 1/5 1/5 4/5 1/5 4/5 1/5
2026-04-28 C+ 2/5 1/5 1/5 4/5 1/5 4/5 1/5
2026-04-27 C+ 2/5 1/5 1/5 4/5 1/5 4/5 1/5
2026-04-24 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-04-23 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-04-22 C 2/5 1/5 1/5 4/5 1/5 3/5 1/5
2026-04-20 C+ 2/5 1/5 1/5 5/5 1/5 3/5 1/5
2026-04-17 C+ 2/5 1/5 1/5 5/5 1/5 3/5 1/5
2026-04-16 C+ 2/5 1/5 1/5 5/5 1/5 3/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
2.17M
OE per share TTM
0.00
Owner's Yield
85.75%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
97.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
8.3K
Shares Outstanding
520.76M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Ester Vigil President 352.1K female
Brian Farrell Interim Chief Executive Officer & Interim Chairman of the Board 152.9K male
Jeremy Fong Chief Financial Officer 110.2K male
Brent Hilton Controller — male
Alexia Helgason Vice President of Investor Relations — female
Kathy Estochin Vice President of Finance & Administration — female
Marion McGrath Company Secretary — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic